<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 的股价在周五的午盘交易中下跌了 6%。该公司的股价最低曾达到 9.34 美元，最后交易价为 9.3690 美元。在午盘交易中，共交易了 449,473 股，较平均交易量 1,620,085 股下降了 72%。该股票之前的收盘价为 9.97 美元。</p>
<h2>分析师评级调整</h2>
<p>几家券商最近对 DAWN 进行了评论。Needham &amp; Company LLC 在 11 月 24 日的研究报告中重申了对 Day One Biopharmaceuticals 的 “买入” 评级，并设定了 16.00 美元的目标价。Weiss Ratings 在周一的报告中重申了对 Day One Biopharmaceuticals 的 “卖出（d-）” 评级。摩根大通将 Day One Biopharmaceuticals 的目标价从 26.00 美元上调至 27.00 美元，并在 11 月 7 日的研究报告中给予该公司 “增持” 评级。Piper Sandler 在 11 月 5 日的研究报告中将 Day One Biopharmaceuticals 的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “增持” 评级。最后，Zacks Research 在 10 月 13 日的研究报告中将 Day One Biopharmaceuticals 的评级从 “持有” 上调至 “强烈买入”。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Day One Biopharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 24.43 美元。</p>
<p><strong>查看我们关于 Day One Biopharmaceuticals 的最新研究报告</strong></p>
<h2>Day One Biopharmaceuticals 价格表现</h2>
<p>该股票的市值为 9.8213 亿美元，市盈率为-6.29，贝塔值为-1.27。该股票的 50 日简单移动平均线为 8.33 美元，200 日简单移动平均线为 7.38 美元。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近在 11 月 4 日发布了季度财报。该公司报告每股收益为-0.19 美元，超出市场共识预期的-0.28 美元，超出幅度为 0.09 美元。Day One Biopharmaceuticals 的净利润率为-113.53%，股本回报率为-32.05%。该公司季度收入为 3980 万美元，而分析师预期为 3820 万美元。在去年同期，该公司每股收益为 0.38 美元。该公司的收入同比下降了 57.6%。整体来看，分析师预计 Day One Biopharmaceuticals, Inc.在本财年将发布每股收益-0.72 美元。</p>
<h2>Day One Biopharmaceuticals 内部交易</h2>
<p>在其他 Day One Biopharmaceuticals 的新闻中，内部人士 Adam Dubow 在 11 月 17 日的交易中出售了 4319 股该公司的股票。股票以平均价格 8.91 美元出售，总交易额为 38482.29 美元。交易后，该内部人士持有公司 62626 股，价值 557997.66 美元。此交易代表其持股减少了 6.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上查阅。此外，首席执行官 Jeremy Bender 在 11 月 17 日的交易中出售了 15894 股公司的股票。股票以平均价格 8.91 美元出售，总价值为 141615.54 美元。出售后，首席执行官持有公司 177165 股，价值约 1578540.15 美元。此交易使其持股减少了 8.23%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 28001 股公司股票，价值 249489 美元。内部人士持有公司股票的比例为 6.20%。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近调整了对 DAWN 的持股。Hudson Bay Capital Management LP 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 1.8%。Hudson Bay Capital Management LP 目前拥有 1320000 股该公司的股票，价值 9306000 美元，在此期间又购买了 23300 股。Tudor Investment Corp ET AL 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 36.2%。Tudor Investment Corp ET AL 目前拥有 49550 股该公司的股票，价值 349000 美元，在上个季度又购买了 13157 股。PharVision Advisers LLC 在第三季度购买了价值约 299000 美元的 Day One Biopharmaceuticals 新股份。XTX Topco Ltd 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 224.9%。XTX Topco Ltd 目前拥有 78848 股该公司的股票，价值 556000 美元，在上个季度又收购了 54580 股。最后，Polymer Capital Management US LLC 在第三季度购买了价值约 134000 美元的 Day One Biopharmaceuticals 新股份。机构投资者持有公司 87.95% 的股票。</p>
<h2>Day One Biopharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向疗法的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中关注经过充分验证的癌症分子驱动因素，Day One 旨在提供具有重要临床益处的首创或最佳疗法。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而非 Day One Biopharmaceuticals</li>
<li>电话会议与个人投资者</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远是</li>
<li>META 在科技下滑中上涨，分析师称赞特朗普的人工智能命令</li>
<li>2025 年有潜力的两只 CRM 平台股票</li>
<li>TL;DR：为什么 Reddit 是新的增长股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Day One Biopharmaceuticals 吗？</h2>
<p>在你考虑 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Day One Biopharmaceuticals 并不在名单上。</p>
<p>虽然 Day One Biopharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DAWN

<p>Day One Biopharmaceuticals 的股票在午盘交易中下跌了 6%，交易量显著减少。分析师的评级不一，有些对该股票进行了升级，而另一些则进行了下调。内部人士的销售被报告，机构投资者也调整了他们的持股。该公司报告的季度收益好于预期，但同比收入大幅下降</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s stock price fell 6% during mid-day trading on Friday . The company traded as low as $9.34 and last traded at $9.3690. 449,473 shares were traded during mid-day trading, a decline of 72% from the average session volume of 1,620,085 shares. The stock had previously closed at $9.97.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 的股价在周五的午盘交易中下跌了 6%。该公司的股价最低曾达到 9.34 美元，最后交易价为 9.3690 美元。在午盘交易中，共交易了 449,473 股，较平均交易量 1,620,085 股下降了 72%。该股票之前的收盘价为 9.97 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several brokerages recently commented on DAWN. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Day One Biopharmaceuticals in a report on Monday. JPMorgan Chase &amp; Co. raised their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 7th. Piper Sandler upped their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, November 5th. Finally, Zacks Research raised shares of Day One Biopharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $24.43.</p>
<div class="lb-trans"><p>几家券商最近对 DAWN 进行了评论。Needham &amp; Company LLC 在 11 月 24 日的研究报告中重申了对 Day One Biopharmaceuticals 的 “买入” 评级，并设定了 16.00 美元的目标价。Weiss Ratings 在周一的报告中重申了对 Day One Biopharmaceuticals 的 “卖出（d-）” 评级。摩根大通将 Day One Biopharmaceuticals 的目标价从 26.00 美元上调至 27.00 美元，并在 11 月 7 日的研究报告中给予该公司 “增持” 评级。Piper Sandler 在 11 月 5 日的研究报告中将 Day One Biopharmaceuticals 的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “增持” 评级。最后，Zacks Research 在 10 月 13 日的研究报告中将 Day One Biopharmaceuticals 的评级从 “持有” 上调至 “强烈买入”。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Day One Biopharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 24.43 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Day One Biopharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Day One Biopharmaceuticals 的最新研究报告</strong></p>
</div><h2>Day One Biopharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 价格表现</h2>
</div><p>The stock has a market capitalization of $982.13 million, a P/E ratio of -6.29 and a beta of -1.27. The stock's 50-day simple moving average is $8.33 and its 200 day simple moving average is $7.38.</p>
<div class="lb-trans"><p>该股票的市值为 9.8213 亿美元，市盈率为-6.29，贝塔值为-1.27。该股票的 50 日简单移动平均线为 8.33 美元，200 日简单移动平均线为 7.38 美元。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. During the same period in the prior year, the firm earned $0.38 earnings per share. The company's revenue was down 57.6% on a year-over-year basis. As a group, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近在 11 月 4 日发布了季度财报。该公司报告每股收益为-0.19 美元，超出市场共识预期的-0.28 美元，超出幅度为 0.09 美元。Day One Biopharmaceuticals 的净利润率为-113.53%，股本回报率为-32.05%。该公司季度收入为 3980 万美元，而分析师预期为 3820 万美元。在去年同期，该公司每股收益为 0.38 美元。该公司的收入同比下降了 57.6%。整体来看，分析师预计 Day One Biopharmaceuticals, Inc.在本财年将发布每股收益-0.72 美元。</p>
</div><h2>Insider Transactions at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 内部交易</h2>
</div><p>In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the transaction, the insider owned 62,626 shares in the company, valued at $557,997.66. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO Jeremy Bender sold 15,894 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the sale, the chief executive officer owned 177,165 shares of the company's stock, valued at approximately $1,578,540.15. The trade was a 8.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 28,001 shares of company stock worth $249,489. Insiders own 6.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Day One Biopharmaceuticals 的新闻中，内部人士 Adam Dubow 在 11 月 17 日的交易中出售了 4319 股该公司的股票。股票以平均价格 8.91 美元出售，总交易额为 38482.29 美元。交易后，该内部人士持有公司 62626 股，价值 557997.66 美元。此交易代表其持股减少了 6.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上查阅。此外，首席执行官 Jeremy Bender 在 11 月 17 日的交易中出售了 15894 股公司的股票。股票以平均价格 8.91 美元出售，总价值为 141615.54 美元。出售后，首席执行官持有公司 177165 股，价值约 1578540.15 美元。此交易使其持股减少了 8.23%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 28001 股公司股票，价值 249489 美元。内部人士持有公司股票的比例为 6.20%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently modified their holdings of DAWN. Hudson Bay Capital Management LP lifted its position in Day One Biopharmaceuticals by 1.8% during the third quarter. Hudson Bay Capital Management LP now owns 1,320,000 shares of the company's stock worth $9,306,000 after purchasing an additional 23,300 shares during the period. Tudor Investment Corp ET AL raised its position in shares of Day One Biopharmaceuticals by 36.2% in the 3rd quarter. Tudor Investment Corp ET AL now owns 49,550 shares of the company's stock valued at $349,000 after buying an additional 13,157 shares in the last quarter. PharVision Advisers LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $299,000. XTX Topco Ltd boosted its position in shares of Day One Biopharmaceuticals by 224.9% during the 3rd quarter. XTX Topco Ltd now owns 78,848 shares of the company's stock worth $556,000 after acquiring an additional 54,580 shares in the last quarter. Finally, Polymer Capital Management US LLC bought a new position in Day One Biopharmaceuticals in the third quarter valued at approximately $134,000. Institutional investors own 87.95% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对 DAWN 的持股。Hudson Bay Capital Management LP 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 1.8%。Hudson Bay Capital Management LP 目前拥有 1320000 股该公司的股票，价值 9306000 美元，在此期间又购买了 23300 股。Tudor Investment Corp ET AL 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 36.2%。Tudor Investment Corp ET AL 目前拥有 49550 股该公司的股票，价值 349000 美元，在上个季度又购买了 13157 股。PharVision Advisers LLC 在第三季度购买了价值约 299000 美元的 Day One Biopharmaceuticals 新股份。XTX Topco Ltd 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 224.9%。XTX Topco Ltd 目前拥有 78848 股该公司的股票，价值 556000 美元，在上个季度又收购了 54580 股。最后，Polymer Capital Management US LLC 在第三季度购买了价值约 134000 美元的 Day One Biopharmaceuticals 新股份。机构投资者持有公司 87.95% 的股票。</p>
</div><h2>Day One Biopharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向疗法的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中关注经过充分验证的癌症分子驱动因素，Day One 旨在提供具有重要临床益处的首创或最佳疗法。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
<li>Conference Calls and Individual Investors</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>TL;DR: Why Reddit is the New Growth Stock to Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Day One Biopharmaceuticals</li>
<li>电话会议与个人投资者</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远是</li>
<li>META 在科技下滑中上涨，分析师称赞特朗普的人工智能命令</li>
<li>2025 年有潜力的两只 CRM 平台股票</li>
<li>TL;DR：为什么 Reddit 是新的增长股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Day One Biopharmaceuticals 吗？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Day One Biopharmaceuticals 并不在名单上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Day One Biopharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Day One Biopharmaceuticals (NASDAQ:DAWN) 的股价下跌了 6% - 接下来会发生什么？